BioVie Announces Best Efforts Offering of Stock & Warrants
BioVie Inc. filed an S-1 registration statement for a 'best efforts' offering of Class A Common Stock and Pre-funded Warrants, with no minimum offering amount and an expected termination by September 30, 2026. The company plans to use the proceeds for working capital and general corporate purposes, including R&D. In clinical development, the Phase 2b Parkinson's Disease trial is expected to report topline results late summer 2026, and the Long COVID program received a $13.1 million grant. However, the Phase 3 Alzheimer's Disease trial faced significant protocol deviations at multiple sites, leading to patient exclusions and an underpowered study, and the company is also involved in securities class action litigation.
Key Highlights
- Announced a 'best efforts' offering of Class A Common Stock and Pre-funded Warrants.
- Offering price based on Nasdaq's $1.77 per share on July 15, 2026.
- Offering will terminate by September 30, 2026, with no minimum offering amount.
- Net proceeds to be used for working capital and general corporate purposes, including R&D.
- Phase 2b Parkinson's Disease trial expects topline results late summer 2026.
- Long COVID program received a $13.1 million grant from the U.S. Department of War.
- Alzheimer's Disease Phase 3 trial experienced significant protocol deviations at 15 sites.
- Company is subject to ongoing securities class action litigation.
Price Impact
More from BIVI